^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Rituxan Hycela (rituximab/hyaluronidase) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/16/2022
Excerpt:
Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.
